The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
FGF-21 as a novel metabolic regulator
Open accessAbstract
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, FGF21 stimulates the uptake of glucose by adipocytes and inhibits the production of glucose in the liver.”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“FGF21 acts in the control of glucose and lipid homeostasis (Kharitonenkov et al., 2005).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, FGF21 appears to protect pancreatic β cells from cell death induced by glycotoxicity (Kharitonenkov et al., 2005, 2007).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, mice that overexpress FGF-21, a circulating FGF which is induced by a ketogenic diet 106, are lean and have increased brown fat 107, suggesting that the beneficial metabolic effects induced by a ketogenic diet are brought about in part by increases in BAT mass.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [107]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“overexpression of FGF21 is highly protective [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“activation of the FGF21/FGFR1c/KLB receptor complex results in the phosphorylation of ERK1/2 and FRS2α [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In rodents, pharmacological levels of FGF21 increase energy expenditure (64, 141), which results in increased food intake (54, 64).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In addition, FGF21 enhances insulin sensitivity in primary brown adipocytes (86) but not in primary white adipocytes (64, 86).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [114]
In the citing paper
“Fibroblast growth factor 21 (FGF21) was first identified as an hepatokine 61 and has been shown to be necessary for the adaptation to fasting 62, 63.”
From Inter‐organ communication: a gatekeeper for metabolic health (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
SIGNALLING BY RECEPTOR TYROSINE KINASES
Fantl, W. J., Johnson, D. E., & Williams, L. T. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.62.1.453 · Cited by 1,118
Cheatham, B., Vlahos, C. J., Cheatham, L. A., Wang, L., Blenis, J., & Kahn, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4902-4911.1994 · Cited by 1,062
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Flagged first, then by citations
Research works printed but not linked: 3
- Konishi, 1999, J. Biol. Chem., 255, 12119
- Shah, 2000, J. Clin. Endocrinol. Metab., 85, 4053
- Cheatham, 1994, Mol. Cell. Biol., 14, 4902, 10.1128/MCB.14.7.4902 · DOI
Cited by
Sorted by citations
Items 301–400 of 1,008
Kharitonenkov, A. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.07.001 · Cited by 133
PGC-1α negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erbα axis
Estall, J. L., Ruas, J. L., Choi, C. S., Laznik, D., Badman, M. K., Maratos–Flier, E., Shulman, G. I., & Spiegelman, B. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912533106 · Cited by 135
Xu, L., & Ota, T. (2017) · Adipocyte · doi:10.1080/21623945.2017.1413516 · Cited by 134
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 142
Regulation of myokine expression: Role of exercise and cellular stress
Ost, M., Coleman, V., Kasch, J., & Klaus, S. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.02.018 · Cited by 135
Zhang, Y., Yeh, L., Zhang, S., Call, M. K., Yuan, Y., Yasunaga, M., Kao, W. W. ‐., & Liu, C. (2015) · Development · doi:10.1242/dev.125393 · Cited by 131
Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation
Tanimura, Y., Aoi, W., Takanami, Y., Kawai, Y., Mizushima, K., Naito, Y., & Yoshikawa, T. (2016) · Physiological Reports · doi:10.14814/phy2.12828 · Cited by 131
Serum FGF21 levels are associated with brown adipose tissue activity in humans
Hanssen, M. J. W., Broeders, E. P. M., Samms, R. J., Vosselman, M. J., van der Lans, A. A. J. J., Cheng, C., Adams, A. C., Lichtenbelt, W. D. V. M., & Schrauwen, P. (2015) · Scientific Reports · doi:10.1038/srep10275 · Cited by 136
Stress-induced FGF21 and GDF15 in obesity and obesity resistance
Keipert, S., & Ost, M. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.08.008 · Cited by 132
Hui, X., Zhu, W., Wang, Y., Lam, K. S. L., Zhang, J., Wu, D., Kraegen, E. W., Li, Y., & Xu, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.001107 · Cited by 130
Zhang, F., Yu, L., Lin, X., Cheng, P., He, L., Li, X., Lu, X., Tan, Y., Yang, H., Cai, L., et al. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1155 · Cited by 130
Feingold, K. R., Grünfeld, C., Heuer, J. G., Gupta, A., Cramer, M. S., Zhang, T., Shigenaga, J. K., Patzek, S. M., Chan, Z. W., Moser, A. H., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1496 · Cited by 130
Fibroblast growth factor receptors, developmental corruption and malignant disease
Kelleher, F. C., O’Sullivan, H., Smyth, E., McDermott, R., & Viterbo, A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt254 · Cited by 131
Youm, Y.-H., Horvath, T. L., Mangelsdorf, D. J., Kliewer, S. A., & Dixit, V. D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514511113 · Cited by 129
Lin, Z., Zhou, Z., Liu, Y., Gong, Q., Yan, X., Xiao, J., Wang, X., Lin, S., Feng, W., & Li, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018398 · Cited by 130
Fibroblast Growth Factor 21 (FGF21) in Human Cerebrospinal Fluid
Tan, B. K., Hallschmid, M., Adya, R., Kern, W., Lehnert, H., & Randeva, H. S. (2011) · Diabetes · doi:10.2337/db11-0672 · Cited by 129
Roles of FGF19 in Liver MetabolismPreprint
Kır, S., Kliewer, S. A., & Mangelsdorf, D. J. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010710 · Cited by 128
Novel Insights into the Cardio-Protective Effects of FGF21 in Lean and Obese Rat Hearts
Patel, V., Adya, R., Chen, J., Ramanjaneya, M., Bari, M. F., Bhudia, S. K., Hillhouse, E. W., Tan, B. K., & Randeva, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087102 · Cited by 124
Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates
Lundsgaard, A.-M., Fritzen, A. M., Sjøberg, K. A., Myrmel, L. S., Madsen, L., Wojtaszewski, J. F. P., Richter, E. A., & Kiens, B. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.001 · Cited by 126
Actions and Mode of Actions of FGF19 Subfamily Members
Fukumoto, S. (2008) · Endocrine Journal · doi:10.1507/endocrj.kr07e-002 · Cited by 125
Fibroblast Growth Factor 21 Predicts the Metabolic Syndrome and Type 2 Diabetes in Caucasians
Bobbert, T., Schwarz, F., Fischer‐Rosinsky, A., Pfeiffer, A. F. H., Möhlig, M., Mai, K., & Spranger, J. (2012) · Diabetes Care · doi:10.2337/dc12-0703 · Cited by 125
Molecular mechanisms underlying physical exercise-induced brain BDNF overproduction
Cefis, M., Chaney, R., Wirtz, J., Méloux, A., Quirié, A., Leger, C., Prigent‐Tessier, A., & Garnier, P. E. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1275924 · Cited by 145
Benomar, Y., & Taouis, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00140 · Cited by 131
FGF21 and Cardiac Physiopathology
Planavila, A., Redondo-Angulo, I., & Villarroya, F. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00133 · Cited by 123
Kim, S. H., Kim, K. H., Kim, H.-K., Kim, M.-J., Back, S. H., Konishi, M., Itoh, N., & Lee, M.-S. (2015) · Diabetologia · doi:10.1007/s00125-014-3475-6 · Cited by 124
FGF21 mediates the lipid metabolism response to amino acid starvation
De Sousa-Coelho, A. L., Relat, J., Hondares, E., Pérez-Martí, A., Ribas, F., Villarroya, F., Marrero, P. F., & Haro, D. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m033415 · Cited by 123
Long-Term Cold Adaptation Does Not Require FGF21 or UCP1
Keipert, S., Kutschke, M., Ost, M., Schwarzmayr, T., van Schothorst, E. M., Lamp, D., Brachthäuser, L., Hamp, I., Mazibuko, S. E., Hartwig, S., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.016 · Cited by 122
Yu, Y., Bai, F., Wang, W., Liu, Y., Yuan, Q., Qu, S., Zhang, T., Tian, G., Li, S., Li, D., et al. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.03.020 · Cited by 119
Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans
Hansen, J. S., Clemmesen, J. O., Secher, N. H., Hoene, M., Drescher, A., Weigert, C., Pedersen, B. K., & Plomgaard, P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.06.001 · Cited by 123
Huang, J., Ishino, T., Chen, G., Rolzin, P., Osothprarop, T. F., Retting, K., Li, L., Jin, P., Matin, M. J., Huyghe, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204420 · Cited by 121
Fibroblast growth factor 21: a regulator of metabolic disease and health span
Xie, T., & Leung, P. S. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00101.2017 · Cited by 121
Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine
Tan, H., Tong, Y. A., Chen, Z., Wu, W., Xu, S., & Weng, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73936 · Cited by 119
Role of Osteoglycin in the Linkage between Muscle and Bone
Tanaka, K.-I., Matsumoto, E., Higashimaki, Y., Katagiri, T., Sugimoto, T., Seino, S., & Kaji, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.292193 · Cited by 121
Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
Itoh, N., Ohta, H., & Konishi, M. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00154 · Cited by 119
Tanaka, N., Takahashi, S., Zhang, Y., Krausz, K. W., Smith, P. B. W., Patterson, A. D., & Gonzalez, F. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.02.012 · Cited by 120
Assini, J. M., Mulvihill, E. E., Burke, A. C., Sutherland, B. G., Telford, D. E., Chhoker, S. S., Sawyez, C. G., Drangova, M., Adams, A. C., Kharitonenkov, A., et al. (2015) · Endocrinology · doi:10.1210/en.2014-2003 · Cited by 119
Haluzíková, D., Lacinová, Z., Kaválková, P., Drápalová, J., Křížová, J., Bártlová, M., Mráz, M., Petr, T., Vı́tek, L., Kasalicky, M., et al. (2013) · Obesity · doi:10.1002/oby.20208 · Cited by 118
Li, H., Dong, K., Fang, Q., Hou, X., Zhou, M., Bao, Y., Xiang, K., Xu, A., & Jia, W. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.029 · Cited by 118
mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes
Minard, A. Y., Tan, S., Yang, P., Fazakerley, D. J., Domanova, W., Parker, B. L., Humphrey, S. J., Jothi, R., Stöckli, J., & James, D. E. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.086 · Cited by 122
Targeting FGFR for cancer therapy
Zhang, P., Yue, L., Leng, Q., Chen, C., Gan, C., Ye, T., & Cao, D. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01558-1 · Cited by 130
The role of Klotho in energy metabolism
Razzaque, M. S. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.75 · Cited by 117
Wei, W., An, X.-R., Jin, S., Li, X.-X., & Xu, M. (2018) · Scientific Reports · doi:10.1038/s41598-017-18427-2 · Cited by 116
Cytochrome P450S and Alcoholic Liver Disease
Lu, Y., & Cederbaum, A. I. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180410091511 · Cited by 116
Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress
Yang, C., Lu, W., Lin, T., You, P., Ye, M., Huang, Y., Jiang, X., Wang, C., Wang, F., Lee, M., et al. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-67 · Cited by 117
Metabolic crosstalk between choline/1-carbon metabolism and energy homeostasis
Zeisel, S. H. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0518 · Cited by 119
Mäkelä, J., Tselykh, T. V., Maiorana, F., Eriksson, O., Thi, H., Mudò, G., Korhonen, L., Belluardo, N., & Lindholm, D. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-2 · Cited by 119
ER-associated degradation in health and disease – from substrate to organism
Bhattacharya, A., & Qi, L. (2019) · Journal of Cell Science · doi:10.1242/jcs.232850 · Cited by 109
Glycosaminoglycan affinity of the complete fibroblast growth factor family
Asada, M., Shinomiya, M., Suzuki, M., Honda, E., Sugimoto, R., Ikekita, M., & Imamura, T. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.09.001 · Cited by 118
Muscle-Adipose Tissue Cross TalkPreprint
Stanford, K. I., & Goodyear, L. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029801 · Cited by 119
Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21
Domouzoglou, E. M., Naka, K. Κ., Vlahos, A. P., Papafaklis, M. I., Michalis, L. K., Tsatsoulis, A., & Maratos–Flier, E. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00527.2015 · Cited by 115
Stanislaus, S., Hecht, R. I., Yie, J., Hager, T., Hall, M. P., Spahr, C. S., Wang, W., Weiszmann, J., Li, Y., Deng, L., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1917 · Cited by 114
Joki, Y., Ohashi, K., Yuasa, D., Shibata, R., Ito, M., Matsuo, K., Kambara, T., Uemura, Y., Hayakawa, S., Hiramatsu‐Ito, M., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.081 · Cited by 114
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
Kharitonenkov, A., & DiMarchi, R. D. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.007 · Cited by 114
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression
Huang, Q., Wu, M., Wu, X., Zhang, Y., & Xia, Y. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188761 · Cited by 124
Zhang, C., Huang, Z., Gu, J., Yan, X., Lu, X., Zhou, S., Wang, S., Shao, M., Zhang, F., Cheng, P., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3630-8 · Cited by 113
Gupte, A. A., Lyon, C. J., & Hsueh, W. A. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0372-1 · Cited by 114
Clinical relevance of FGF-23 in chronic kidney disease
Seiler, S., Heine, G. H., & Fliser, D. (2009) · Kidney International · doi:10.1038/ki.2009.405 · Cited by 115
Nutritionally-Induced Catch-Up Growth
Gat‐Yablonski, G., & Phillip, M. (2015) · Nutrients · doi:10.3390/nu7010517 · Cited by 119
Iglesias, P., Selgas, R., Romero, S., & Díez, J. J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0357 · Cited by 113
Dorling, J. L., Martin, C. K., & Redman, L. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101038 · Cited by 104
Metabolic Changes of Hepatocytes in NAFLD
Lu, Q., Tian, X., Wu, H., Huang, J., Li, M., Mei, Z., Zhou, L., Xie, H., & Zheng, S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.710420 · Cited by 118
Singhal, G., Fisher, F. M., Chee, M. J. S., Tan, T. G., Ouaamari, A. E., Adams, A. C., Najarían, R. M., Kulkarni, R., Benoist, C. O., Flier, J. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148252 · Cited by 112
Zapata, L., Pich, O., Serrano, L. G., Kondrashov, F. A., Ossowski, S., & Schaefer, M. H. (2018) · Genome biology · doi:10.1186/s13059-018-1434-0 · Cited by 110
Kim, K. H., Jeong, Y. T., Kim, S. H., Jung, H. S., Park, K. S., Lee, H.-Y., & Lee, M.-S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.026 · Cited by 112
Serum Levels of the Adipokine FGF21 Depend on Renal Function
Stein, S., Bachmann, A., Lössner, U., Kratzsch, J., Blüher, M., Stümvoll, M., & Faßhauer, M. (2008) · Diabetes Care · doi:10.2337/dc08-1054 · Cited by 111
FGF15/FGFR4 Integrates Growth Factor Signaling with Hepatic Bile Acid Metabolism and Insulin Action
Shin, D.-J., & Osborne, T. F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808747200 · Cited by 112
Plasma Concentrations of Fibroblast Growth Factors 19 and 21 in Patients with Anorexia Nervosa
Dostálová, I., Kaválková, P., Haluzíková, D., Lacinová, Z., Mráz, M., Papežová, H., & Haluzı́k, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0746 · Cited by 111
Zhang, Y., Lei, T., Huang, J., Wang, S. B., Zhou, L., Yang, Z., & Chen, X. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.003 · Cited by 110
Caputo, T., Gilardi, F., & Desvergne, B. (2017) · FEBS Letters · doi:10.1002/1873-3468.12742 · Cited by 112
Huang, X., Yu, C., Jin, C., Yang, C., Xie, R., Cao, D., Wang, F., & McKeehan, W. L. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20241 · Cited by 110
Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2317-z · Cited by 110
Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
Adams, A. C., Coskun, T., Irizarry Rovira, A. R., Schneider, M. A., Raches, D. W., Micanovic, R., Bina, H. A., Dunbar, J. D., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038438 · Cited by 109
Self-citationAdipose tissue, diet and aging
Zamboni, M. M., Rossi, A. P., Fantin, F., Zamboni, G. A., Chirumbolo, S., Zoico, E., & Mazzali, G. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.11.008 · Cited by 115
Regulation of glucose homoeostasis by brown adipose tissue
Peirce, V. J., & Vidal‐Puig, A. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70055-x · Cited by 111
Syndecan-1 Is Required to Maintain Intradermal Fat and Prevent Cold Stress
Kasza, I., Suh, Y. K., Wollny, D., Clark, R. J., Roopra, A., Colman, R. J., MacDougald, O. A., Shedd, T. A., Nelson, D. W., Yen, M., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004514 · Cited by 119
Macronutrients and the Adipose-Liver Axis in Obesity and Fatty Liver
Duwaerts, C. C., & Maher, J. J. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.02.001 · Cited by 113
Myokines in metabolic homeostasis and diabetes
Eckel, J. (2019) · Diabetologia · doi:10.1007/s00125-019-4927-9 · Cited by 113
Maternal Overweight Programs Insulin and Adiponectin Signaling in the Offspring
Shankar, K., Kang, P., Harrell, A., Zhong, Y., Marecki, J. C., Ronis, M. J. J., & Badger, T. M. (2010) · Endocrinology · doi:10.1210/en.2010-0017 · Cited by 107
Yu, Y.-H., Bai, F., Liu, Y., Yang, Y., Yuan, Q., Zou, D., Qu, S., Tian, G., Song, L., Zhang, T., et al. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2358-6 · Cited by 108
Geller, S., Arribat, Y., Netzahualcoyotzi, C., Lagarrigue, S., Carneiro, L., Zhang, L., Amati, F., López‐Mejía, I. C., & Pellerin, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.004 · Cited by 117
Li, H., Bao, Y., Xu, A., Pan, X., Lu, J., Wu, H., Lu, H., Xiang, K., & Jia, W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2331 · Cited by 108
Protein-dependent regulation of feeding and metabolism
Morrison, C. D., & Laeger, T. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.02.008 · Cited by 106
Li, X., Ge, H., Weiszmann, J., Hecht, R. I., Li, Y., Véniant, M. M., Xu, J., Wu, X., Lindberg, R. A., & Li, Y. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.09.012 · Cited by 107
So, W. Y., Cheng, Q., Chen, L., Evans‐Molina, C., Xu, A., Lam, K. S. L., & Leung, P. S. (2013) · Diabetes · doi:10.2337/db13-0645 · Cited by 112
Johann, K., Cremer, A. L., Fischer, A. W., Heine, M., Pensado, E. R., Resch, J., Nock, S., Virtue, S., Harder, L., Oelkrug, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.054 · Cited by 114
Trinchese, G., Cavaliere, G., Canani, R. B., Matamoros, S., Bergamo, P., Filippo, C. D., Aceto, S., Gaita, M., Cerino, P., Negri, R., et al. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.05.003 · Cited by 106
Chen, J., HU, J. L., Liu, H., Xiong, Y., Zou, Y., Huang, W., Shao, M., Wu, J., Yu, L., Wang, X., et al. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5271 · Cited by 106
Regulation of FGF21 Expression and Secretion by Retinoic Acid Receptor-related Orphan Receptor α
Wang, Y., Solt, L. A., & Burris, T. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102160 · Cited by 106
FGF21: A Missing Link in the Biology of Fasting
Reitman, M. L. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.010 · Cited by 106
ATF4- and CHOP-Dependent Induction of FGF21 through Endoplasmic Reticulum Stress
Wan, X., Lu, X., Xiao, Y.-C., Lin, Y., Zhu, H., Ding, T., Yang, Y., Huang, Y., Zhang, Y., Liu, Y., et al. (2014) · BioMed Research International · doi:10.1155/2014/807874 · Cited by 110
FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
Sonoda, J., Chen, M. Z., & Baruch, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0002 · Cited by 110
Tong, X., Muchnik, M., Chen, Z., Patel, M., Wu, N., Joshi, S., Rui, L., Lazar, M. A., & Yin, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172866 · Cited by 105
Chartoumpekis, D. V., & Kensler, T. W. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309020005 · Cited by 105
Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability
Huang, Z., Tan, Y., Gu, J., Liu, Y., Song, L., Niu, J., Zhao, L., Srinivasan, L., Lin, Q., Deng, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.063 · Cited by 103
Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells
Hu, C., Qiao, W., Li, X. O., Ning, Z., Liu, J., Dalangood, S., Li, H., Yu, X., Zong, Z., Wen, Z., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.01.005 · Cited by 116
Zhao, C., Liu, Y., Xiao, J., Liu, L., Chen, S., Mohammadi, M., McClain, C. J., Li, X., & Feng, W. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m058610 · Cited by 105
Hanks, L. J., Gutiérrez, O. M., Bamman, M. M., Ashraf, A., McCormick, K. L., & Casazza, K. (2015) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2015.02.001 · Cited by 104
Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi
Xiong, X., Wang, Q., Wang, S., Zhang, J., Liu, T., Guo, L., Yu, Y., & Lin, J. D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.004 · Cited by 100
Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis
Markan, K. R., & Potthoff, M. J. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.09.021 · Cited by 103
New therapeutic approaches for the treatment of obesity
Saltiel, A. R. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1811 · Cited by 102
Metadata
- Authors
- Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D.-S., Mehrbod, F., Jaskunas, S. R., & Shanafelt, A. B.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1627-1635
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1088017
- OpenAlex
- W2000665430
- Cited by
- 2,125
- References
- 46
- Citations by year
- 2026: 72 · 2025: 99 · 2024: 111 · 2023: 120 · 2022: 137 · 2021: 138 · 2020: 116 · 2019: 136 · 2018: 147 · 2017: 135 · 2016: 142 · 2015: 155 · 2014: 124 · 2013: 125 · 2012: 115
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Hospital for Sick Children
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, diabetes mellitus, glucose uptake, adipocytes, diet-induced obesity, transgenic mice, ob/ob mice, db/db mice, plasma glucose, triglycerides, metabolic regulation, diabetes treatment
- MeSH terms
- Animals, Blood Glucose, Cell Division, Cells, Cultured, Diabetes Mellitus, Fibroblast Growth Factors, Humans, Hyperglycemia, Hypoglycemic Agents, Mice, Obese, Mice, Transgenic, Triglycerides, Weight Gain, Adipocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
